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Historical background
As early as 1965 it was proposed that in addition to the
well-established second messengers, cyclic AMP and cyclic
GMP, the cyclic pyrimidine nucleotides, cyclic CMP
(cCMP) and cyclic UMP (cUMP) could play a role as sec-
ond messenger molecules. This hypothesis was based on
the identification of cCMP- and cUMP-hydrolyzing phos-
phodiesterase (PDE) activities in mammalian tissues [1,2].
Additionally, extracellular effects of cCMP on cell prolif-
eration were reported [3], but unfortunately, those effects
were not reproduced. Moreover, a specific cytidylyl cyclase
activity was proposed, but the methodology used was
questionable [4,5]. Furthermore, cCMP and cUMP were
supposedly identified by fast atom bombardment mass
spectrometry, but the methodology was not sufficiently
accurate for unequivocal mass determination of cCMP
and cUMP [6]. Because of the substantial methodological
problems, the cCMP and cUMP field had been largely
abandoned. Our recent discovery that the bacterial “adeny-
lyl” cyclase toxins, CyaA from Bordetella pertussis and
edema factor from Bacillus anthracis, also exhibit substan-
tial cytidylyl- and uridylyl cyclase activity as assessed by
radiometric assays [7], renewed interest in the cCMP and
cUMP field.
Methodology
In order to critically re-evaluate the cCMP- and cUMP
field, we developed highly sensitive quantitative HPLC-
MS/MS mass spectrometry methods to detect multiple
cyclic nucleotides (cNMPs). Unequivocal detection of
cNMPs was achieved by determination of the accurate
mass of the intact cNMPs and defined cNMP fragments.
The MS methodology allowed us to determine cNMP
levels in intact cells, organs and body fluids and to
detect nucleotidyl cyclase- and PDE activities. As poten-
tial targets for cCMP and cUMP, we examined cAMP-
and cGMP-activated protein kinases. For intact cell
studies, we took advantage of the (Sp)-stereoisomers of
cNMPSs and acetoxymethylesters of cNMPs. In order to
identify cCMP- and cUMP-binding proteins, we used
cNMP-agarose resins.
Results and discussion
Taking advantage of the HPLC-MS/MS methodology, we
detected cCMP and cUMP in numerous cultured cell
types and in human urine. Growth-arrest of cells resulted
in preferential decrease of cellular cCMP- and cUMP
concentrations as compared to cAMP- and cGMP con-
centrations, indicating that cCMP- and cUMP produc-
tion is dependent on factors present in serum. Known
adenylyl and guanylyl cyclases exhibit, to different
extents, cytidylyl- and uridylyl cyclase activities. The
cNMP agarose affinity chromatography technique identi-
fied cAMP-dependent protein kinase as one target
protein for cCMP and cUMP, these cNMPs being low-
affinity activators of this kinase. Moreover, several
recombinant cAMP- and cGMP-degrading PDEs were
identified to exhibit cUMP-degrading activity, whereas to
this end, we have not been able to identify a cCMP-
hydrolyzing PDE. Finally, cCMP- and cUMP-acetoxy-
methylesters are capable of inducing differentiation of
neuronal cells. In conclusion, (i) cCMP and cUMP are
present at substantial concentrations in various cells
types, (ii) cCMP- and cUMP concentrations are regulated
by the cell proliferation status, (iii) cUMP is degraded by
known PDEs, and (iv) biological effects of cCMP and
cUMP are beginning to be unmasked. All these data are
i n d i c a t i v ef o rar o l eo fc C M Pa n dc U M Pa s( o l d )n e w
second messenger molecules.
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